The interdependent influence of lobbying and intellectual capital on new drug development

Vareska Van De Vrande, Annapoornima M. Subramanian, Moren Lévesque and Patricia Klopf

Research Policy, 2024, vol. 53, issue 2

Abstract: Pharmaceutical firms are top lobbying spenders in the United States (US). While the potential benefits of lobbying are recognized in the literature, the criticism against unethical aspects of lobbying warrants pharmaceutical firms to strategize their lobbying activities. Our study addresses the question “How does a pharmaceutical firm's resource allocation decision toward lobbying activities (and other non-market activities) influence that firm's new drug launches and do these non-market activities interact with market activities?” Specifically, we investigate the interaction between lobbying and the intellectual capital (human, structural, and social capital) of firms. We use a formal model to develop our hypotheses, which we test on a sample of the largest US-listed pharmaceutical firms between 1999 and 2021. Our analyses suggest that human and structural capital weaken the effect of lobbying on the firm's rate of new drug launches, whereas a firm's social capital strengthens the relationship between lobbying and the rate of new drug launches.

Keywords: Lobbying intensity; Lobbying breadth; Intellectual capital; Non-market strategy; New drug development (search for similar items in EconPapers)
Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S0048733323002226
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:respol:v:53:y:2024:i:2:s0048733323002226

DOI: 10.1016/j.respol.2023.104938

Access Statistics for this article

Research Policy is currently edited by M. Bell, B. Martin, W.E. Steinmueller, A. Arora, M. Callon, M. Kenney, S. Kuhlmann, Keun Lee and F. Murray

More articles in Research Policy from Elsevier
Bibliographic data for series maintained by Catherine Liu ().